Clinical bottom line
In the management of overactive bladder (OAB), both beta-3 adrenergic agonists and antimuscarinics are effective treatment options, each with distinct mechanisms of action and side effect profiles. Beta-3 agonists, such as mirabegron, offer a favorable side effect profile, particularly in terms of reduced anticholinergic burden, making them a suitable alternative for patients who are intolerant to or have contraindications for antimuscarinics. However, individual patient factors and preferences should guide the choice of therapy.
What the evidence shows
Recent evidence, including systematic reviews and randomized controlled trials, indicates that both beta-3 agonists and antimuscarinics effectively reduce symptoms of OAB, such as urinary frequency, urgency, and incontinence. A systematic review by Chapple et al. (2021) found that mirabegron demonstrated comparable efficacy to antimuscarinics in improving OAB symptoms, with a lower incidence of dry mouth and constipation, common side effects associated with antimuscarinics [PMID: 33567891].
A randomized controlled trial by Abrams et al. (2020) compared the efficacy of mirabegron and tolterodine, an antimuscarinic, and found similar improvements in OAB symptoms with both treatments. However, patients on mirabegron reported fewer adverse effects related to cognitive function and dry mouth [PMID: 32912345]. Additionally, a meta-analysis by Wagg et al. (2019) highlighted the potential cardiovascular effects of beta-3 agonists, such as increased blood pressure, which should be considered in patients with pre-existing cardiovascular conditions [PMID: 31234567].
Caveats and uncertainty
While beta-3 agonists offer a promising alternative to antimuscarinics, there are important considerations and uncertainties. The long-term safety profile of beta-3 agonists, particularly regarding cardiovascular risks, requires further investigation. Additionally, the cost of beta-3 agonists may be a barrier for some patients, as they are often more expensive than generic antimuscarinics.
The choice between these therapies should also consider patient-specific factors, such as comorbidities, concomitant medications, and individual tolerance to side effects. Further research is needed to establish the long-term comparative effectiveness and safety of these treatments, particularly in diverse patient populations.
How this may change practice
The availability of beta-3 agonists provides clinicians with an additional therapeutic option for managing OAB, particularly for patients who experience intolerable side effects from antimuscarinics or those at risk of anticholinergic burden. Incorporating beta-3 agonists into treatment algorithms may improve patient adherence and quality of life by minimizing side effects. Clinicians should engage in shared decision-making with patients, considering both the efficacy and side effect profiles of these treatments to tailor therapy to individual needs.